6 results about "Cellular biomarkers" patented technology

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

The present invention provides a method for selecting a cancer patient for a cancer treatment or for predicting or monitoring the response of a cancer patient to a cancer treatment, comprising: determining the level of effector regulatory T cells in a biological sample from the patient, wherein said level of effector regulatory T cells correlates with the responsiveness of said patient to the cancer treatment.

This invention belongs to the field of cell detection technology, specifically involving the application of NR4A1 as an early biomarker for gamma-ray radiation. This invention discovers that in the early stage (2 hours) after gamma-ray radiation, the protein and mRNA levels of NR4A1 are significantly increased, exhibiting a radiation dose-dependent effect. NR4A1 can serve as a 2-hour biomarker for gamma-ray irradiated HeLa cells, allowing for the screening of cells irradiated for 2 hours, differentiating the duration of gamma-ray irradiation, and achieving early diagnosis of cellular gamma-ray radiation.

The invention aims to provide a method for separating and amplifying placenta decidua matrix cells in a perinatal period. The method comprises the following steps: adding decidua tissues into a culture medium A containing collagenase for digestion treatment; cleaning to obtain a cell suspension A, and sieving to obtain a cell suspension B; mixing the cell suspension B with a Ficoll solution, and carrying out primary gradient centrifugation; mixing the cell layer and the supernate layer with normal saline, and then carrying out secondary gradient centrifugation; and culturing the cell block mass and the culture medium B in an incubator. According to the method, the success rate of separation and amplification of the placenta decidua interstitial cells in the perinatal period can be increased, the separated and proliferated cells have group cell biomarker expression for tissue repair, and the separation technical method is improved, so that highly purified cells are obtained.

The invention relates to a biomarker of periapical cells and application of the biomarker, and belongs to the technical field of biological detection. The objective of the invention is to solve the problem that a conventional periodontal cell marker has expression overlap with other interstitial cells under an anoxic condition, cannot accurately distinguish tip periodontal cell subgroups, and hinders functional research and targeted therapy development thereof. The method comprises the following steps: screening 15 specific genes (including Adamts9, Cd93, Ctla2a, Fkbp1a, Angpt2 and the like) as periapical cell biomarkers by adopting machine learning according to brain single cell sequencing data of a high-altitude hypoxia mouse; and constructing a logistic regression prediction model to realize cell identification. According to the biomarker combination and the biomarker model, the false detection rate (lt; 5%). A new molecular marker for accurately identifying periapical cells is developed through a machine learning method based on a big data set, and a brand new breakthrough is provided for developing hypoxia response type periapical cell specific markers and functional targets.

The present invention provides diagnostic methods, therapeutic methods, and therapeutic compositions for lymphoma (e.g., diffuse large B-cell lymphoma (e.g., hair center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The present invention is based, at least in part, on the discovery that macrophage biomarkers can be used in methods for identifying, diagnosing, or predicting the efficacy of treatment with an anti-CD79b immunoconjugate (e.g., vipostuzumab) and an anti-CD20 antibody (e.g., ototuzumab or rituximab).